| Product NDC: | 0069-1001 |
| Proprietary Name: | XELJANZ |
| Non Proprietary Name: | TOFACITINIB CITRATE |
| Active Ingredient(s): | 5 mg/1 & nbsp; TOFACITINIB CITRATE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0069-1001 |
| Labeler Name: | Pfizer Laboratories Div Pfizer Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA203214 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20121109 |
| Package NDC: | 0069-1001-03 |
| Package Description: | 28 TABLET, FILM COATED in 1 BOTTLE (0069-1001-03) |
| NDC Code | 0069-1001-03 |
| Proprietary Name | XELJANZ |
| Package Description | 28 TABLET, FILM COATED in 1 BOTTLE (0069-1001-03) |
| Product NDC | 0069-1001 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | TOFACITINIB CITRATE |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20121109 |
| Marketing Category Name | NDA |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Substance Name | TOFACITINIB CITRATE |
| Strength Number | 5 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes |